| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Molecular sequelae of proteasome inhibition in human multiple myeloma cells.
|
Proc Natl Acad Sci U S A
|
2002
|
4.33
|
|
2
|
Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
|
Semin Oncol
|
2003
|
3.88
|
|
3
|
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.
|
Blood
|
2002
|
3.01
|
|
4
|
Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.
|
Oncogene
|
2002
|
2.66
|
|
5
|
Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.
|
Blood
|
2012
|
2.29
|
|
6
|
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.
|
Br J Haematol
|
2005
|
1.99
|
|
7
|
The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia.
|
Blood
|
2007
|
1.99
|
|
8
|
Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells.
|
Blood
|
2002
|
1.97
|
|
9
|
Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications.
|
Blood
|
2002
|
1.92
|
|
10
|
Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia.
|
J Clin Oncol
|
2008
|
1.89
|
|
11
|
Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications.
|
Cancer Res
|
2005
|
1.84
|
|
12
|
Diagnosis and management of Waldenstrom's macroglobulinemia.
|
J Clin Oncol
|
2005
|
1.82
|
|
13
|
International prognostic scoring system for Waldenstrom macroglobulinemia.
|
Blood
|
2009
|
1.81
|
|
14
|
MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction.
|
Blood
|
2013
|
1.79
|
|
15
|
Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma.
|
Blood
|
2010
|
1.79
|
|
16
|
Infectious complications associated with alemtuzumab use for lymphoproliferative disorders.
|
Clin Infect Dis
|
2006
|
1.78
|
|
17
|
Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications.
|
Cancer Res
|
2003
|
1.51
|
|
18
|
A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.
|
Blood
|
2013
|
1.44
|
|
19
|
Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia.
|
Clin Lymphoma Myeloma
|
2006
|
1.44
|
|
20
|
Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications.
|
Cancer Res
|
2004
|
1.42
|
|
21
|
The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis.
|
Blood
|
2013
|
1.38
|
|
22
|
Targeting NF-kappaB in Waldenstrom macroglobulinemia.
|
Blood
|
2008
|
1.36
|
|
23
|
Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
|
Semin Oncol
|
2003
|
1.33
|
|
24
|
Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism.
|
Blood
|
2007
|
1.29
|
|
25
|
Amyloidosis and Waldenström's macroglobulinemia.
|
Hematology Am Soc Hematol Educ Program
|
2004
|
1.29
|
|
26
|
Multiple myeloma.
|
J Natl Compr Canc Netw
|
2011
|
1.28
|
|
27
|
Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice.
|
Exp Hematol
|
2007
|
1.26
|
|
28
|
Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia.
|
Blood
|
2007
|
1.24
|
|
29
|
Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications.
|
Blood
|
2006
|
1.21
|
|
30
|
Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia.
|
J Clin Oncol
|
2010
|
1.18
|
|
31
|
Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia.
|
Blood
|
2008
|
1.16
|
|
32
|
Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs.
|
J Clin Oncol
|
2008
|
1.15
|
|
33
|
Multiple myeloma, version 1.2013.
|
J Natl Compr Canc Netw
|
2013
|
1.14
|
|
34
|
Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop.
|
Br J Haematol
|
2012
|
1.14
|
|
35
|
Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
|
Semin Oncol
|
2003
|
1.13
|
|
36
|
Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).
|
Clin Cancer Res
|
2006
|
1.11
|
|
37
|
Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy.
|
Clin Lymphoma Myeloma
|
2007
|
1.07
|
|
38
|
Proteomic analysis of waldenstrom macroglobulinemia.
|
Cancer Res
|
2007
|
1.07
|
|
39
|
Clonotypic IgM V/D/J sequence analysis in Waldenstrom macroglobulinemia suggests an unusual B-cell origin and an expansion of polyclonal B cells in peripheral blood.
|
Blood
|
2004
|
1.05
|
|
40
|
Hyperviscosity-related retinopathy in waldenstrom macroglobulinemia.
|
Arch Ophthalmol
|
2006
|
1.04
|
|
41
|
CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling.
|
Blood
|
2002
|
1.03
|
|
42
|
Balancing risk versus benefit in the treatment of Waldenström's Macroglobulinemia patients with nucleoside analogue-based therapy.
|
Clin Lymphoma Myeloma
|
2009
|
1.02
|
|
43
|
Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia.
|
Am J Hematol
|
2010
|
0.98
|
|
44
|
Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia.
|
J Clin Oncol
|
2010
|
0.98
|
|
45
|
Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia.
|
Clin Cancer Res
|
2008
|
0.97
|
|
46
|
Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
|
Semin Oncol
|
2003
|
0.96
|
|
47
|
Proteomic analyses in Waldenstrom's macroglobulinemia and other plasma cell dyscrasias.
|
Semin Oncol
|
2003
|
0.95
|
|
48
|
Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma.
|
Br J Haematol
|
2004
|
0.95
|
|
49
|
Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma.
|
Mol Cancer Ther
|
2012
|
0.94
|
|
50
|
Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia.
|
Leuk Lymphoma
|
2008
|
0.94
|
|
51
|
IgA and IgG hypogammaglobulinemia in Waldenström's macroglobulinemia.
|
Haematologica
|
2009
|
0.94
|
|
52
|
Molecular characterization of Waldenstrom's macroglobulinemia reveals frequent occurrence of two B-cell clones having distinct IgH VDJ sequences.
|
Clin Cancer Res
|
2007
|
0.91
|
|
53
|
The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia.
|
Br J Haematol
|
2008
|
0.91
|
|
54
|
CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia.
|
Blood
|
2008
|
0.89
|
|
55
|
Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia.
|
Am J Hematol
|
2014
|
0.89
|
|
56
|
Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013.
|
J Natl Compr Canc Netw
|
2012
|
0.89
|
|
57
|
CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders.
|
Clin Lymphoma Myeloma
|
2006
|
0.89
|
|
58
|
Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma.
|
ACS Chem Biol
|
2014
|
0.88
|
|
59
|
Novel biologically based therapies for Waldenstrom's macroglobulinemia.
|
Semin Oncol
|
2003
|
0.88
|
|
60
|
Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database.
|
Br J Haematol
|
2014
|
0.87
|
|
61
|
Hepatitis C viral infection is not associated with Waldenström's macroglobulinemia.
|
Am J Hematol
|
2007
|
0.87
|
|
62
|
Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemia.
|
Clin Lymphoma Myeloma
|
2009
|
0.87
|
|
63
|
Inherited and acquired variations in the hyaluronan synthase 1 (HAS1) gene may contribute to disease progression in multiple myeloma and Waldenstrom macroglobulinemia.
|
Blood
|
2008
|
0.87
|
|
64
|
Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells.
|
Br J Haematol
|
2003
|
0.86
|
|
65
|
Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia.
|
Blood
|
2008
|
0.85
|
|
66
|
Ophthalmologic techniques to assess the severity of hyperviscosity syndrome and the effect of plasmapheresis in patients with Waldenström's macroglobulinemia.
|
Clin Lymphoma Myeloma
|
2009
|
0.84
|
|
67
|
CD5, CD10, and CD23 expression in Waldenstrom's macroglobulinemia.
|
Clin Lymphoma
|
2005
|
0.84
|
|
68
|
Hyperphosphorylated paratarg-7: a new molecularly defined risk factor for monoclonal gammopathy of undetermined significance of the IgM type and Waldenstrom macroglobulinemia.
|
Blood
|
2011
|
0.83
|
|
69
|
A SCID-hu in vivo model of human Waldenström macroglobulinemia.
|
Blood
|
2005
|
0.83
|
|
70
|
Waldenström macroglobulinemia: from biology to treatment.
|
Expert Rev Hematol
|
2014
|
0.83
|
|
71
|
Effect of plasmapheresis on hyperviscosity-related retinopathy and retinal hemodynamics in patients with Waldenstrom's macroglobulinemia.
|
Invest Ophthalmol Vis Sci
|
2008
|
0.82
|
|
72
|
Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenström macroglobulinemia cells.
|
Leuk Lymphoma
|
2011
|
0.82
|
|
73
|
Matrix metalloproteinase-8 is overexpressed in Waldenström's macroglobulinemia cells, and specific inhibition of this metalloproteinase blocks release of soluble CD27.
|
Clin Lymphoma Myeloma Leuk
|
2011
|
0.81
|
|
74
|
CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenström macroglobulinaemia cells.
|
Br J Haematol
|
2014
|
0.81
|
|
75
|
Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemia.
|
Clin Lymphoma Myeloma
|
2009
|
0.81
|
|
76
|
Multiple Myeloma, Version 2.2016.
|
J Natl Compr Canc Netw
|
2015
|
0.81
|
|
77
|
Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia.
|
Br J Haematol
|
2009
|
0.81
|
|
78
|
Potential impact of a single nucleotide polymorphism in the hyaluronan synthase 1 gene in Waldenstrom's macroglobulinemia.
|
Clin Lymphoma
|
2005
|
0.79
|
|
79
|
Family history of non-hematologic cancers among Waldenstrom macroglobulinemia patients: a preliminary study.
|
Cancer Epidemiol
|
2011
|
0.79
|
|
80
|
Histone deacetylase inhibitors demonstrate significant preclinical activity as single agents, and in combination with bortezomib in Waldenström's macroglobulinemia.
|
Clin Lymphoma Myeloma Leuk
|
2011
|
0.79
|
|
81
|
Transcriptional repression of plasma cell differentiation is orchestrated by aberrant over-expression of the ETS factor SPIB in Waldenström macroglobulinaemia.
|
Br J Haematol
|
2014
|
0.78
|
|
82
|
Inhibition of the Bruton Tyrosine Kinase Pathway in B-Cell Lymphoproliferative Disorders.
|
Cancer J
|
2016
|
0.78
|
|
83
|
Bortezomib as a treatment option in patients with Waldenström macroglobulinemia.
|
Clin Lymphoma Myeloma Leuk
|
2010
|
0.78
|
|
84
|
Biology, prognosis, and therapy of Waldenström Macroglobulinemia.
|
Cancer Treat Res
|
2015
|
0.78
|
|
85
|
microRNA aberrations in Waldenström macroglobulinemia.
|
Clin Lymphoma Myeloma Leuk
|
2013
|
0.78
|
|
86
|
MYD88-independent growth and survival effects of Sp1 transactivation in Waldenstrom macroglobulinemia.
|
Blood
|
2014
|
0.77
|
|
87
|
The malignant clone in Waldenstrom's macroglobulinemia.
|
Semin Oncol
|
2003
|
0.77
|
|
88
|
Hepcidin is produced by lymphoplasmacytic cells and is associated with anemia in Waldenström's macroglobulinemia.
|
Clin Lymphoma Myeloma Leuk
|
2011
|
0.77
|
|
89
|
Fcγ receptor predictive genomic testing and the treatment of indolent non-Hodgkin lymphoma.
|
Clin Lymphoma Myeloma Leuk
|
2010
|
0.75
|
|
90
|
Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias.
|
Biologics
|
2008
|
0.75
|
|
91
|
Associated malignancies in patients with Waldenström's macroglobulinemia and their kin.
|
Clin Lymphoma Myeloma Leuk
|
2011
|
0.75
|
|
92
|
Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
|
J Natl Compr Canc Netw
|
2017
|
0.75
|
|
93
|
Clinical relevance of soluble HLA class I molecules in Waldenstrom Macroglobulinemia.
|
Eur J Haematol
|
2008
|
0.75
|
|
94
|
Challenges with serum protein electrophoresis in assessing progression and clinical response in patients with Waldenström macroglobulinemia.
|
Clin Lymphoma Myeloma Leuk
|
2013
|
0.75
|
|
95
|
Comparative response assessment by serum immunoglobulin M M-protein and total serum immunoglobulin M after treatment of patients with Waldenström macroglobulinemia.
|
Clin Lymphoma Myeloma Leuk
|
2013
|
0.75
|